Galenvs Sciences (Galenvs) is the latest company to join Emergence, Atlantic Canada’s bioscience business incubator which is dedicated to assisting start-ups and growth-stage companies in the commercialization of bioscience-based technologies and services. Galenvs leads the way in precision development and scalable manufacturing of nanomaterials and DNA/RNA oligonucleotides for therapeutic and diagnostic applications.
Already a trusted provider in Quebec and Western Canada, Galenvs is now focused on expanding into the Maritimes while accelerating its growth into global markets. The company offers end-to-end services spanning proof-of-concept, in-vitro validation, pilot-scale production, and beyond.
“We are pleased to have Galenvs join Emergence,” said Jason Cleaversmith, Director of Incubation, PEI BioAlliance. “Galenvs brings expertise in precision nanotechnology and oligonucleotide synthesis that is set to drive significant advancements in diagnostics and therapeutics. Through Emergence, we look forward to connecting Galenvs with key partners in product design, testing, and biomanufacturing.”
Founded on principles of innovation, excellence, and collaboration, Galenvs is powered by a team of seasoned experts who specialize in leveraging multidisciplinary technologies. Galenvs employs data-driven methodologies and customized process-driven strategies to empower clients in achieving their biotechnology objectives, including sample purification, and advanced therapeutic development.
Galenvs’ proprietary multidisciplinary technologies in functional nanomaterials and oligonucleotide synthesis deliver unmatched value for their healthcare providers, diagnostic developers, and industry partners. The company thrives on addressing complex challenges, designing tailored, scalable solutions, and optimizing products for diverse applications.
“Our participation in Emergence represents an exciting milestone for Galenvs,” said Jamal Daoud, Galenvs’ Chief Executive Officer, “With the support of the Emergence program and its robust network, we are poised to build on our existing success as we continue delivering tangible solutions for health challenges.”
Emergence provides companies with business incubation services including the Critical Path program, one-on-one and team mentorship, business strategy and advisory services, as well as access to the Emergence Performance Network. Emergence Advisor Eddie Francis specializes in contract research development and growth, supporting companies such as Galenvs, and ensuring the company maximizes its potential during this next phase of expansion.